---
title: "SINOPHARM Group: Our group, SINOPHARM Traditional Chinese Medicine, and the Chinese Medicinal Materials Co., Ltd. have no equity or control relationship with each other"
description: "Sinopharm Group stated that its subsidiary, China Traditional Chinese Medicine Co., Ltd., has transferred its 25% equity stake in Sinopharm Medicinal Materials Co., Ltd. to Shanghai Tianyue Tenghua Tr"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261599579.md"
published_at: "2025-10-17T10:13:30.000Z"
---

# SINOPHARM Group: Our group, SINOPHARM Traditional Chinese Medicine, and the Chinese Medicinal Materials Co., Ltd. have no equity or control relationship with each other

> Sinopharm Group stated that its subsidiary, China Traditional Chinese Medicine Co., Ltd., has transferred its 25% equity stake in Sinopharm Medicinal Materials Co., Ltd. to Shanghai Tianyue Tenghua Trading Service Co., Ltd. After the transfer, Sinopharm Traditional Chinese Medicine no longer holds any equity in Medicinal Materials Co. There is no equity or control relationship between Sinopharm Group and Medicinal Materials Co. At the same time, Medicinal Materials Co. has used the "Sinopharm Group" related name and trademark without authorization, which constitutes infringement, and the Group has initiated legal proceedings to hold them accountable

Sinopharm Group stated that its subsidiary, China Traditional Chinese Medicine Co., Ltd., has publicly listed the transfer of 25% of its shares in Sinopharm Medicinal Materials Co., Ltd. through the Beijing Equity Exchange. After the completion of the share transfer, Sinopharm Traditional Chinese Medicine will no longer hold any shares in Medicinal Materials Co., Ltd., and there is no equity or control relationship between our group, Sinopharm Traditional Chinese Medicine, and Medicinal Materials Co., Ltd. Medicinal Materials Co., Ltd. and its affiliated enterprises have repeatedly and unauthorizedly used the "Sinopharm Group" related name, trademarks, and franchise rights without authorization, which constitutes serious infringement. Legal proceedings have been initiated to firmly pursue their responsibility

### Related Stocks

- [01099.HK - SINOPHARM](https://longbridge.com/en/quote/01099.HK.md)
- [00570.HK - TRAD CHI MED](https://longbridge.com/en/quote/00570.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sinopharm Group (SEHK:1099): Valuation Check After Renewing Shanghai Henlius Distribution Partnership | Sinopharm Group's renewed distribution partnership with Shanghai Henlius Biotech extends their collaboration until 2028. | [Link](https://longbridge.com/en/news/269631888.md) |
| 'Punk wellness': China's stressed youth mix traditional medicine and cocktails | In Shanghai, a bar named 'Niang Qing' combines traditional Chinese medicine (TCM) with cocktails, catering to stressed y | [Link](https://longbridge.com/en/news/275852718.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/en/news/276056763.md) |
| Obeikan Glass Changes Its Trading Name From "Obeikan Glass" To "OGC" | OBEIKAN GLASS :OBEIKAN GLASS - CHANGES ITS TRADING NAME FROM "OBEIKAN GLASS" TO "OGC" | [Link](https://longbridge.com/en/news/276033502.md) |
| Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/en/news/276113491.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.